ALGS

MKT CAP:$40M

Aligos Therapeutics, Inc.

Market Cap

$40M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$6.13-$3.00 (-32.86%)

Apr 23, 2026

Company Details

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting...

CEO

Lawrence Blatt

IPO Date

Oct 16, 2020

Website

www.aligos.com

Key Metrics TTM

Revenue

$2M

-44.6% YoY

Net Income

-$24M

EPS (Diluted)

-$8.59

Free Cash Flow

-$83M

Revenue / Share

$0.21

Gross Margin

76.4%

Operating Margin

-4024.9%

Net Margin

-1106.7%

FCF Margin

-3794.1%

P/S

18.1x

P/E

—

Earnings Reports

Q1 2026

May 5, 2026

PENDING

FY 2025

Mar 5, 2026

$2M-44.6%EPS -$2.45

Q4 2025

Mar 5, 2026

$169.0K-73.1%EPS -$1.91

Q3 2025

Nov 6, 2025

$741.0K-41.6%EPS -$3.04

Q2 2025

Aug 6, 2025

$965.0K-9.0%EPS -$1.53

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$3M	$3M	-$36M
Q2 22	$4M	$4M	-$20M
Q3 22	$4M	$4M	-$19M
Q4 22	$4M	$4M	-$23M
Q1 23	$3M	$3M	-$24M
Q2 23	$7M	$7M	-$19M
Q3 23	$3M	$3M	-$19M
Q4 23	$3M	$3M	-$26M
Q1 24	$986.0K	$986.0K	-$22M
Q2 24	$1M	$451.0K	-$26M
Q3 24	$1M	$1M	-$20M
Q4 24	$629.0K	$629.0K	-$21M
Q1 25	$311.0K	$311.0K	-$19M
Q2 25	$965.0K	$706.0K	-$19M
Q3 25	$741.0K	$741.0K	-$28M
Q4 25	$169.0K	-$88.0K	-$22M

Valuation

Quarter	P/S	P/E
Q1 22	6.6x	—
Q2 22	4.8x	—
Q3 22	3.7x	—
Q4 22	2.8x	—
Q1 23	2.8x	—
Q2 23	2.3x	—
Q3 23	2.4x	—
Q4 23	2.6x	—
Q1 24	2.9x	—
Q2 24	5.0x	—
Q3 24	6.6x	—
Q4 24	10.0x	—
Q1 25	12.1x	—
Q2 25	12.5x	—
Q3 25	15.0x	—
Q4 25	18.1x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$20M	-$21M
Q2 22	-$25M	-$25M
Q3 22	-$17M	-$17M
Q4 22	-$17M	-$17M
Q1 23	-$22M	-$22M
Q2 23	-$14M	-$14M
Q3 23	-$20M	-$20M
Q4 23	-$23M	-$23M
Q1 24	-$23M	-$23M
Q2 24	-$19M	-$20M
Q3 24	-$20M	-$20M
Q4 24	-$18M	-$18M
Q1 25	-$21M	-$21M
Q2 25	-$16M	-$16M
Q3 25	-$24M	-$25M
Q4 25	-$22M	-$22M

Capital Expenditures

Quarter	CapEx
Q1 22	$515.0K
Q2 22	$334.0K
Q3 22	$3.0K
Q4 22	$91.0K
Q1 23	$7.0K
Q2 23	$7.0K
Q3 23	$12.0K
Q4 23	$7.0K
Q1 24	$69.0K
Q2 24	$7.0K
Q3 24	$26.0K
Q4 24	$28.0K
Q1 25	$43.0K
Q2 25	$109.0K
Q3 25	$193.0K
Q4 25	$92.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	+182.5%	+33.1%
Q2 22	+139.0%	-22.6%
Q3 22	+167.1%	-33.4%
Q4 22	+863.8%	-31.6%
Q1 23	+5.9%	-30.1%
Q2 23	+86.5%	+8.1%
Q3 23	-21.1%	-3.2%
Q4 23	-24.2%	+9.4%
Q1 24	-63.8%	-13.5%
Q2 24	-84.6%	+5.6%
Q3 24	-60.8%	-4.1%
Q4 24	-76.5%	-26.1%
Q1 25	-68.5%	-15.1%
Q2 25	-9.0%	-28.9%
Q3 25	-41.6%	+36.0%
Q4 25	-73.1%	+3.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$4M	147.3%
Q2 22	$4M	108.3%
Q3 22	$3M	85.0%
Q4 22	$3M	96.6%
Q1 23	$4M	134.6%
Q2 23	$3M	46.4%
Q3 23	$3M	99.1%
Q4 23	$3M	96.3%
Q1 24	$3M	268.6%
Q2 24	$2M	193.8%
Q3 24	$2M	161.0%
Q4 24	$2M	271.1%
Q1 25	$959.0K	308.4%
Q2 25	$1M	120.2%
Q3 25	$0	0.0%
Q4 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$32M	$6M	—
Q2 22	$17M	$8M	—
Q3 22	$18M	$5M	—
Q4 22	$19M	$7M	—
Q1 23	$18M	$9M	—
Q2 23	$17M	$9M	—
Q3 23	$16M	$6M	—
Q4 23	$22M	$6M	—
Q1 24	$16M	$7M	—
Q2 24	$21M	$6M	—
Q3 24	$17M	$5M	—
Q4 24	$16M	$5M	—
Q1 25	$15M	$5M	—
Q2 25	$14M	$6M	—
Q3 25	$24M	$5M	—
Q4 25	$17M	—	$5M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$105M	$79M	$183M
Q2 22	$71M	$88M	$159M
Q3 22	$86M	$56M	$142M
Q4 22	$81M	$44M	$126M
Q1 23	$79M	$25M	$104M
Q2 23	$91M	$10.0K	$91M
Q3 23	$70M	$0	$70M
Q4 23	$136M	$0	$136M
Q1 24	$24M	$89M	$113M
Q2 24	$45M	$49M	$95M
Q3 24	$35M	$40M	$75M
Q4 24	$37M	$20M	$57M
Q1 25	$74M	$64M	$138M
Q2 25	$19M	$104M	$123M
Q3 25	$42M	$57M	$99M
Q4 25	$18M	$60M	$78M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	43M	+0.4%	+13.6%
Q2 22	43M	+0.4%	+13.4%
Q3 22	43M	+0.2%	+0.9%
Q4 22	43M	+0.2%	+1.2%
Q1 23	43M	+0.2%	+0.9%
Q2 23	43M	+0.7%	+1.3%
Q3 23	43M	+0.7%	+1.7%
Q4 23	25M	-42.8%	-41.9%
Q1 24	16M	-37.4%	-63.7%
Q2 24	6M	-59.8%	-85.5%
Q3 24	6M	+0.1%	-85.6%
Q4 24	6M	+0.2%	-74.7%
Q1 25	9M	+38.6%	-44.1%
Q2 25	10M	+18.8%	+65.2%
Q3 25	10M	+0.2%	+65.3%
Q4 25	10M	+0.1%	+65.3%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$27.6K	93
Q2 22	$39.7K	93
Q3 22	$44.2K	93
Q4 22	$42.6K	83
Q1 23	$32.8K	83
Q2 23	$83.0K	83
Q3 23	$39.0K	83
Q4 23	$40.6K	66
Q1 24	$14.9K	66
Q2 24	$16.1K	66
Q3 24	$19.2K	66
Q4 24	$9.0K	70
Q1 25	$4.4K	70
Q2 25	$13.8K	70
Q3 25	$10.6K	70
Q4 25	$2.1K	82

Revenue / Employee